Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
17.11
+0.78 (4.78%)
At close: Apr 26, 2024, 4:00 PM
16.86
-0.25 (-1.46%)
After-hours: Apr 26, 2024, 7:47 PM EDT
Company Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.
It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.
The company was founded in 2002 and is headquartered in South San Francisco, California.
Gyre Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 593 |
| CEO | Dr. Han Ying Ph.D. |
Contact Details
Address: 12770 High Bluff Drive, Suite 150 San Diego, California 92130 United States | |
| Phone | (619) 949-3681 |
| Website | gyretx.com |
Stock Details
| Ticker Symbol | GYRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D109 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nassim Usman Ph.D. | President, Chief Executive Officer and Director |
| Seline E. Miller CPA | Senior Vice President of Finance, Interim Chief Financial and Principal Accounting Officer |
| Dr. Grant Blouse M.Sc., Ph.D. | Chief Scientific Officer |
| Ana Kapor | Senior Director of Investor Relations and Corporate Communications |
| Dr. Tom Knudsen D.V.M., Ph.D. | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 9, 2024 | 144 | Filing |
| Apr 8, 2024 | 144 | Filing |
| Apr 5, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | 10-K | Annual Report |